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 
Abstract—Co-crystal is believed to improve the solubility and 
dissolution rates and thus, enhanced the bioavailability of poor water 
soluble drugs particularly during the oral route of administration. 
With the existing of poorly soluble drugs in pharmaceutical industry, 
the screening of co-crystal formation using carbamazepine (CBZ) as 
a model drug compound with dicarboxylic acids co-crystal formers 
(CCF) namely fumaric (FA) and succinic (SA) acids in ethanol has 
been studied. The co-crystal formations were studied by varying the 
mol ratio values of CCF to CBZ to access the effect of CCF 
concentration on the formation of the co-crystal. Solvent evaporation, 
slurry and cooling crystallization which representing the solution 
based method co-crystal screening were used. Based on the 
differential scanning calorimetry (DSC) analysis, the melting point of 
CBZ-SA in different ratio was in the range between 188oC-189oC. 
For CBZ-FA form A and CBZ-FA form B the melting point in 
different ratio were in the range of 174oC-175oC and 185oC-186oC 
respectively. The product crystal from the screening was also 
characterized using X-ray powder diffraction (XRPD). The XRPD 
pattern profile analysis has shown that the CBZ co-crystals with FA 
and SA were successfully formed for all ratios studied. The findings 
revealed that CBZ-FA co-crystal were formed in two different 
polymorphs. It was found that CBZ-FA form A and form B were 
formed from evaporation and slurry crystallization methods 
respectively. On the other hand, in cooling crystallization method, 
CBZ-FA form A was formed at lower mol ratio of CCF to CBZ and 
vice versa. This study disclosed that different methods and mol ratios 
during the co-crystal screening can affect the outcome of co-crystal 
produced such as polymorphic forms of co-crystal and thereof. Thus, 
it was suggested that careful attentions is needed during the screening 
since the co-crystal formation is currently one of the promising 
approach to be considered in research and development for 
pharmaceutical industry to improve the poorly soluble drugs.  
 
Keywords—Carbamazepine, co-crystal, co-crystal former, 
dicarboxylic acid. 
I. INTRODUCTION 
RUG molecules with limited aqueous solubility are the 
common issue in the research and development portfolios 
of discovery focused pharmaceutical companies [1]. 
Pharmaceutical development will be challenging as the issue 
of poor solubility of drug molecule may possibly cause to 
slow dissolution in biological fluids, insufficient and 
inconsistent systemic exposure and consequent lack efficacy 
in patients, particularly when delivered through the oral route 
of administration [1]. In the pharmaceutical industry, it is the 
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poor biopharmaceutical properties rather than toxicity or lack 
of efficacy that are the main reasons why less than 1% of 
active pharmaceutical compounds sometime produce into the 
marketplace [2]. Among these biopharmaceutical properties, 
solubility remains a key [1], with drugs often damaged during 
commercial production due to their low solubility. 
Currently, one of the main challenges for the 
pharmaceutical industry is to improve the solubility of drug. 
The improvement of solubility and dissolution profiles of 
these drug molecules without changing the molecular structure 
is a special challenge for the successful development of 
pharmaceutical products [3]. Since a long time ago, there is 
the interest in the design of pharmaceutical co-crystals, which 
becomes as a potential method for improving the 
bioavailability of drugs with low aqueous solubility [4]. The 
improvements in the pharmaceutical sciences have provided 
several ways for solving the issues of low aqueous solubility 
[1]. Although some techniques are effective in order to 
improve the oral bioavailability, the successes of the ways are 
dependent at times on the specific physicochemical nature of 
the molecules being studied [1]. Therefore, a pharmaceutical 
co-crystal can be designed with the aims to improve the solid-
state properties of an API without influence its natural 
structure [4]. A solution based method is carried out in order 
to determine the possibility of the formation of co-crystals 
from two components.  
II.  MATERIALS AND METHODS 
A. Chemicals 
The CBZ, SA and FA were purchased from Sigma-Aldrich. 
The absolute ethanol was supplied by Fisher Scientific. All the 
chemicals used were with purity exceeding 99%. 
B. Experimental 
The experimental work was conducted using solution based 
approach via solvent evaporation, slurry crystallization and 
cooling crystallization methods [5]. Different mol ratios of 
CCF (SA and FA) to CBZ were prepared each with the 
interval of 0.25 started from 1.0 to 3.0. All the resulting solids 
from each method were separated using vacuum filter at room 
temperature. The solid produced from the experimental work 
were characterized using differential scanning calorimetry 
(DSC), x-ray powder diffraction (XRPD) and optical 
microscopy.  
C. Solvent Evaporation 
A mixture of CBZ with CCF with pre-defined mol ratios 
was dissolved in ethanol using an orbital shaker at a room 
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temperature. Once the solute had fully dissolved, the solution 
was filtered using 0.22 μm syringe filter to remove any 
impurities. The filtered solution was filled in the 20 ml vial 
and covered with parafilm, with a few holes poked in and left 
to evaporate at room temperature. 
D. Slurry Crystallization 
A mixture of CBZ with CCF with pre-defined mol ratios 
was slurried in 10 ml of ethanol for 72 hours of equilibration 
time at room temperature in the shaker. 
E. Cooling Crystallization 
A mixture of CBZ with CCF in 10 ml of ethanol with pre-
defined mol ratios was heated to 60°C for 1 hour in the shaker. 
Once the solute had fully dissolved, the solution was then 
cooled down at 5°C for every 1 hour interval until room 
temperature to induce the precipitation. 
F. Crystal Characterization  
Differential scanning calorimetry (DSC) was used to 
determine the melting point of the co-crystal produced. A 
mortar and pestle was used to ground the sample crystal in 
order to get a small size of sample for a better and more 
uniform thermal contact with the crucible pan. 2 to 3 mg of 
sample was crimped in aluminium pan and analysed in the 
DSC from 30 to 220oC (CBZ-SA) and 30 to 300oC (CBZ-FA), 
with a flow rate of 50 ml/min of nitrogen gas purging at a 
heating rate of 10 oC/min. 
The x-ray powder diffraction (XRPD) pattern profile of the 
produced crystal was identified using RIGAKU (Miniflex II) 
diffractometer with Cu Kα radiation. The system was operated 
at 30 kV and 15 mA with the 2θ (angle) from 3° to 40°. The 
step size and step time were 0.01° and 1 second/step, 
respectively. In addition, the morphology of the crystal was 
characterized using Dino-eye microscope eye-piece and Carl 
Zeiss model microscope. 
III. RESULT AND DISCUSSION 
A. Differential Scanning Calorimetry (DSC) 
The melting point for CBZ as shown in Table I was in good 
agreement with the literature which is 191oC [6] and in the 
range between 190oC-191oC [7]. For FA pure component, the 
measured melting point was detected at 293oC which in the 
temperature range between 287oC-302oC as reported in 
literature [8]. The melting point for SA which is 187oC is near 
the reported by previous study [9]. From the analysis, the 
melting point of CBZ-SA was in the range between 188oC-
189oC as similar to reported study [10], [11]. CBZ-FA form A 
was found to be a hydrate co-crystal as proven by DSC which 
showing a melting between 118oC-125oC representing the 
existing of water followed by melting of the co-crystal at a 
range of 174oC-175oC [10]. 
B. X-ray Powder Diffraction (XRPD) 
Fig. 1 shows a peak profile for the starting materials used in 
this study i.e. CBZ, FA and SA. The CBZ used in this research 
was CBZ form III confirmed by previously reported pattern 
profile [12]. In addition, the CCFs (SA and α form FA) pattern 
profiles were also been identified similar to previously 
reported [9] and [13] respectively. 
 
TABLE I 
DSC ANALYSIS RESULTS 




CBZ-FA form A 118–125 
 174-175 




Fig. 1 XRPD profile for pure components (CBZ, FA and SA) 
 
 
Fig. 2 XRPD profile for CBZ, CBZ-SA and SA 
 
 




CBZ-FA form B 
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Figs. 2 and 3 show an example of the PXRD pattern profile 
for CBZ-SA and CBZ-FA obtained from the screening method 
respectively. Data analysis from the PXRD pattern profiles 
obtained has shown that the co-crystal was successfully 
formed as summarized in Table II.  
 
TABLE II 






form B CBZ-SA 
  
 
   
1.00      
1.25 Slurry 
crystallization 
     
1.50      
1.75       
2.00      
2.25       
2.50      
2.75       




   
1.00      
1.25      
1.50      
1.75      
2.00      
2.25      
2.50      
2.75       




   
1.00      
1.25      
1.50      
1.75      
2.00      
2.25      
2.50      
2.75      
3.00      
 
The findings revealed that CBZ-FA co-crystal has formed 
into two different polymorphic forms depending on the 
crystallization method and the ratio of FA to CBZ. On the 
other hand, the CBZ-SA has only one polymorphic form. The 
CBZ-FA form A was found to be formed for all range of ratios 
studied via solvent evaporation method and at ratios FA to 
CBZ below 1.5 in cooling crystallization method, whereas, 
CBZ-FA form B was found to be formed for all range of ratios 
studied via slurry crystallization method and at ratios FA to 
CBZ above 1.5 in cooling crystallization method. The impact 
from the movement of the particle in the slurry during shaking 
and concentration of the FA in the solution are believed to 
have an effect on the formation of different co-crystal 
polymorphs [14]. Previously, the CBZ-FA co-crystal Form A 
and Form B was reported to be formed from saturated aqueous 
and near saturated or saturated ethanolic solution respectively 
[10].  
C. Morphology 
Fig. 4 shows the needle-like morphology of CBZ-FA and 
CBZ-SA co-crystals similar to previously reported [15]. The 
findings revealed no significant differences between CBZ-FA 
form A and form B as both have needle-like morphology. The 
size of the co-crystal formed by solvent evaporation was 
bigger as compared to cooling and slurry crystallizations. This 
is due to the solvent crystallization method does not involve 
movement of the solution (stirring or shaking) during the 
growing process lead to the co-crystal growth slowly. The 
stirring or shaking process may induce the nucleation and a lot 




(a)                                                     (b) 
Fig. 4 Crystal morphology taken at magnification of 5x for(a) 
CBZ-SA from cooling crystallization at ratio 2.75 and (b) CBZ-FA 
from solvent evaporation at ratio 1.50  
IV. CONCLUSION 
 The findings suggested that it is crucial to conduct a 
multiple methods or approaches during co-crystal screening 
rather than reliance to only one method which may lead to 
inadequate in determination of the co-crystal form. This has 
been proven from the CBZ-FA co-crystal screening in which 
different methods and ratio (concentration) has an effect on 
the polymorphic transformation. This work also could be 
expanded in different solvents in order to find out the 
possibility of co-crystal formation or any polymorphic 
behaviour due to changes of the solvent in the system.  
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